Mission
![Image without a title](https://cdn.lmu-klinikum.de/3c0cfe9bd09883ed/694f5f89fcaf/v/1ebd6645832a/AdobeStock_406635217.jpeg)
As many as two thirds of all psychiatric patients do not respond well to treatment with drugs.
![Image without a title](https://cdn.lmu-klinikum.de/eb225b0319ae73fd/dcafcef88a81/v/5a09fc1e5782/AdobeStock_274238083.jpeg)
While compliance and frequent side effects play a major role, there are also genetic variations which determine whether side effects occur, and which can also prevent medication from working, resulting in reduced or compliance.
![Image without a title](https://cdn.lmu-klinikum.de/42f55d026067b851/2397393398c2/v/9242d10234e4/AdobeStock_296676189.jpeg)
Our international consortium will conduct a pharmacogenomic study to establish the relationship between response to treatment and genetic background.
![Image without a title](https://cdn.lmu-klinikum.de/4f8f37b0bed2676b/2af3bd0844dd/v/ebb0b9b23cbb/AdobeStock_405183312.jpeg)
The research was recently awarded eight million euros in European funding.
Today, medication selection in psychiatry relies on a trial-and-error approach that combines physician experience with clinical indicators. Pharmacogenetic (PGx) testing can help reduce uncertainty in this process by determining the person-specific genetic factors that predict clinical response and side effects associated with genetic variants that impact drug-metabolizing enzymes, drug transporters or drug targets, where differences in metabolism are by far most important.
PSY-PGx is the first non-commercial, large-scale, international initiative with the overarching aim to provide best quality of care, to reduce personal suffering as well as the societal and financial burden of psychiatric disorders. To achieve this, a Clinical Study in psychiatric patients will be performed using individual patient characteristics, including pharmacogenes, to personalize medication prescription.